Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
The Vascular Effects of Vildagliptin in Insulin Resistant Individuals
- Conditions
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Royal Devon and Exeter NHS Foundation Trust
- Target Recruit Count
- 15
- Registration Number
- NCT01122641
- Locations
- 🇬🇧
Diabetes and Vascular Research Department, Exeter, Devon, United Kingdom
Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin
- First Posted Date
- 2010-04-06
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 344
- Registration Number
- NCT01099137
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)
- Conditions
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Institut fur Diabetesforschung, Munich, Germany
- Target Recruit Count
- 140
- Registration Number
- NCT01018602
- Locations
- 🇩🇪
Institut fuer Diabetesforschung, Munich, Germany
Vildagliptin in New Onset Diabetes After Transplantation
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 32
- Registration Number
- NCT00980356
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
- Conditions
- Interventions
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Registration Number
- NCT00936234
- Locations
- 🇩🇪
Department of Cardiology, Frankfurt, Germany
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 798
- Registration Number
- NCT00894868
- Locations
- 🇸🇰
Novartis Investigative Site, Modava Nad Bodvou, Slovakia
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1988
- Registration Number
- NCT00860288
- Locations
- 🇰🇷
Ajou university hospital, Suwon, Korea, Republic of
🇱🇻Daugavpils Regional Hospital, Daugavpils, Latvia
🇱🇻Talsi Clinical Hospital, Talsi, Latvia
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 338
- Registration Number
- NCT00821977
- Locations
- 🇨🇦
G.A. Research Associates Moncton, New Brunswick E1G 1 A7, Moncton, New Brunswick, Canada
🇺🇸AM Diabetes and Endocrinology Center, Bartlett, Tennessee, United States
🇺🇸Ozark Medical-Surgical Associates, Ltd., Springfield, Missouri, United States
Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT00818571
- Locations
- 🇷🇺
Novartis Investigator Site, Moscow, Russian Federation
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00770081
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Emory Clinic, Atlanta, Georgia, United States
🇺🇸Renal Endocrine Associates, P. C., Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.